Friday, April 14
Sessions
Nadine Hempel, PhD
“Oxidative stress adaptations during metastasis: Focus on antioxidant enzyme function and regulation”
3 to 4:30 p.m.
Tangerine Ballroom 3 & 4
Lan G. Coffman, MD, PhD
“Studying the impact of the aging stromal microenvironment on cancer initiation”
4:45 to 6:15 p.m.
Room W311 E-H
Saturday, April 15
Tullia C. Bruno, PhD
“The definition of tertiary lymphoid structures: the knowns and the knowledge gap”
12:30 to 2 p.m.
Room W311 E-H
Sunday, April 16
Session
Constantinos G. Hadjipanayis, MD
“Use of fluorescent guided surgery and theranostic applications in neurosurgery”
1 to 2:30 p.m.
Room W311 A-D
Posters – 1:30 to 5 p.m.
Section 22
Amir Hossein Mohseni, PhD – post-doctoral, University of Pittsburgh
Session: Cancer-associated Inflammation and Microbiome
644 / 17 – Gut microbiota-derived metabolites as regulators of immunity in pre-cancer
Section 28
Laura P. Stabile, PhD – UPMC Hillman Cancer Center
Session: Omics and Imaging Approaches in Cancer Risk, Early Detection, and Response Assessment
Title: 777 / 19 – Super-resolution imaging of heterochromatin structure detects early events in lung cancer
Minisymposium
Itay Raphael, PhD
“T cell receptor (TCR) landscape of childhood brain tumors”
3 to 5 p.m.
Room W307
Monday, April 17
Sessions
Taofeek Owonikoko, MD, PhD
“Putting SCLC in context using emerging clinical and translational insights”
12:30 to 2 p.m.
Room W311 A-D
Greg M. Delgoffe, PhD
Major Symposium: Immunology, Tumor Biology
“Leveraging metabolism to improve cancer immunotherapy”
12:30 to 2 p.m.
Valencia B & C
Jan Beumer, PhD
Novel Antitumor Agents and Targets – Novel Antitumor Agents and Targets
2:30 – 4:30 p.m.
Room W331
Michael J. Becich
Forum: Why Share Data and How to Do It Better?: A SWOT Analysis
“Data sharing leads to more citations, accelerated path to promotion and higher impact of your innovation”
5 to 6:30 p.m.
Room W331
Posters – 9 a.m. to 12:30 p.m.
Section 33 – Board 30
Yu-Chiao (Chris) Chiu, Ph.D./Li-Ju Wang
Session Category: Bioinformatics / Computational Biology / Systems Biology / Convergent Science
Abstract Presentation Number: 2094
Section 21
John C. Schmitz
PO.ET03.06 – Reversal of Drug Resistance
1752 / 17 – Darolutamide reverses osimertinib resistance in non-small cell lung cancer
Section 21
Maria Beecher – Grad student Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA
1762 / 27 – MALT1 is activated by doxorubicin and mediates therapy resistance in triple-negative breast cancer
Section 17
Bill B. Chen – University of Pittsburgh School of Medicine, Pittsburgh, PA
Novel Antitumor agents 3
Track(s) Experimental and Molecular Therapeutics
1619 / 9 – Generation of a novel estrogen receptor degrade
Section 23
Julia Knight – University of Pittsburgh School of Medicine
Track(s) Immunology
PO.IM01.08 – Immunomodulatory Agents and Interventions 1
1798 / 2 – ALDH inhibition as modulator of ovarian tumor associated immune cells
Posters – 1:30 p.m. to 5 p.m.
Section 7
Kaylee Ermine
PhD Candidate, Zhang Lab
University of Pittsburgh, School of Medicine
“Targeting defective necroptosis in colorectal cancer to overcome therapeutic resistance.”
Section 18 – Board 23
Jan Beumer
Title: Pharmacokinetics, bioavailability, and pharmacodynamics of oral triapine
Session Category: Experimental and Molecular Therapeutics
Tuesday, April 18
Sessions
Meet The Expert: Jeremy Rich, MD
Deputy Director, UPMC Hillman Cancer Center
“Epitranscriptomics and Tumor Metabolism”
7 to 7:45 a.m.
Room W311 E-H
Plenary Session
Dario Vignali, PhD
“LAG3: The third checkpoint inhibitor”
8 to 10 a.m.
Vignali – 8:49 to 9:11 a.m.
W Hall A 2-3
Clinical Trial Minisymposium
Jason Luke, MD
“GLIMMER-01: initial results from a phase 1 dose escalation trial of a first-in-class bi-sialidase (E-602) in solid tumors”
2:30 to 4:30 p.m.
Chapin Theater
Forum
Monica Baskin, PhD
“Beyond Platitudes and Proclamations: Meaningful Engagement of Diverse Communities in Cancer Research”
5 to 6:30 p.m.
Room W311 E-H
Posters – 9 a.m. to 12:30 p.m.
Section 37
Murat Ak
PO.CL01.04 – Biomarkers of Therapeutic Benefit 4
Track(s) Clinical Research Excluding Trials
4329 / 4 – Combined extracellular vesicle PD-L1 and radiomics as predictors of response in patients with advanced lung cancer undergoing immunotherapy
Section 40
Sawa Ito
Track(s) Clinical Research Excluding Trials, Immunology
PO.CL07.02 – Immunomodulatory Agents and Interventions
4418 / 4 – Heterogeneity of IFN-γ responsiveness in myeloid malignancies- implication for the possible impact on IFN-γ immunotherapy
Section 40
Juliana Hofstatter Azambuja
Track(s) Clinical Research Excluding Trials,Immunology
4442 / 28 – Dual benefit of MALT1 blockade in glioblastoma
Section 41
Ronghua Wang
Track(s) Clinical Research Excluding Trials,Immunology
PO.CL07.06 – Inflammation, Immunity, and Cancer
4456 / 9 – Inducible nitric oxide synthase (iNOS) and cycloxygenase-2 (COX2) inhibition reprogram the tumor microenvironment and suppress tumor growth in hepatocellular carcinoma
Section 15
Vinod Kumar
Track(s) Experimental and Molecular Therapeutics
PO.ET03.03 – Drug Resistance in Molecular Targeted Therapies 3
3853 / 3 – The TWIST1-p27 signaling pathway is a critical determinant of MET TKI cell cycle arrest and resistance in MET altered non-small cell lung cancer
Posters – 1:30 to 5 p.m.
Section 35
Jian-Hua Luo
Tracks – Molecular/Cellular Biology and Genetics
LB253 / 5 – Long-read single-cell sequencing of liver cancer
Abstract – EMBARGO
Section 46
Jason Luke
Track(s) Clinical Trials
PO.CTP01.01 – Phase I and First-in-Human Clinical Trials in Progress
CT251 / 14 – Phase 1/2 study of HST-1011, an oral CBL-B inhibitor, alone and in combination with anti-PD1 in patients with advanced solid tumors
Abstract – EMBARGO
Section 17
John C. Schmitz
Track(s) Experimental and Molecular Therapeutics, Chemistry
PO.ET01.04 – Targeting Protein Kinases and Phosphatases for Therapy 1
4995 / 8 – Targeting PLK1 effectively suppresses growth of small cell lung cancer
Section 18
Yuzhou Chen
PO.ET01.05 – Targeting Protein Kinases and Phosphatases for Therapy 2
Track(s) Experimental and Molecular Therapeutics,Chemistry
5015 / 7 – Wee1 inhibition and its synthetic lethal combination with Chk1 inhibition in mouse model of neuroendocrine prostate cancer
Section 19 – Board 28
Jan Beumer grad student Josh Deppas poster:
Title: Toxicological characterization and comparison of ATR inhibitors in mice
Session Category: Experimental and Molecular Therapeutics
Session Title: Theranostics and Radionuclides / Pharmacologic Approaches
Published Abstract Number: 5061
Wednesday, April 19
Posters – 9 a.m. to 12:30 p.m.
Section 11
Kasey R. Cargill
PO.MCB09.02 – Metabolism and Metabolomics of Cancer
Track(s) Molecular/Cellular Biology and Genetics
6042 / 15 – Targeting metabolic vulnerabilities in MET-driven lung cancer brain metastases
Section 26
Yen Thi-Hai Pham
Track(s) Population Sciences
PO.PS01.06 – Diet, Alcohol, Tobacco Use, and Other Lifestyle Factors
6449 / 3 – Association between dietary one-carbon metabolism-related nutrients and the risk of colorectal cancer: Findings from the Singapore Chinese Health Study
Access a printable version of UPMC Hillman presenters below.
